LD-2 disclosure · 2nd Quarter - Report
APOTEX CORP.
via APOTEX CORP.
Client
- Name
- APOTEX CORP.
- Location
- Florida · United States of America
Registrant
- Firm
- APOTEX CORP.
- Description
- Generic pharmaceutical manufacturer
- Location
- WESTON, Florida, United States of America
Lobbying activities
1 issueHealth Issues
HR 7667, the Food and Drug Amendments of 2022, Title III, Fees Relating to Generic Drugs, provisions relating to the reauthorization of the Generic Drug User Fee Act; S 4348, Food and Drug Safety and Landmark Advancement Act, Title III, Fees Relating to Generic Drugs, provisions relating to the reauthorization of the Generic Drug User Fee Act; Senator Tina Smith Amendment #1 to S 4348, provisions relating to amending the Hatch-Waxman 180 exclusivity structure to prevent market blockages; HR 2853, the BLOCKING Act, provisions relating to amending the Hatch-Waxman Act 180-day exclusivity structure; and S2910, Expanding Access to Low Cost Generics Act, provisions relating to amending the Hatch-Waxman Act's 180-day exclusivity structure.
LobbyistsSTEVEN GIULI
TargetedSENATE · HOUSE OF REPRESENTATIVES